Comment on: The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis

J Antimicrob Chemother. 2019 Mar 1;74(3):834. doi: 10.1093/jac/dky490.

Authors

O W Akkerman^{1

2}, J W C Alffenaar³

Affiliations

¹ University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands.
² University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, The Netherlands.
³ University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.

PMID: 30508093
DOI: 10.1093/jac/dky490

No abstract available

Publication types

Letter

MeSH terms

Antibiotics, Antitubercular / pharmacology
Antibiotics, Antitubercular / therapeutic use*
Drug Resistance, Bacterial*
Humans
Rifabutin / pharmacology
Rifabutin / therapeutic use*
Rifampin / pharmacology*
Rifampin / therapeutic use
Treatment Outcome
Tuberculosis / diagnosis
Tuberculosis / drug therapy*
Tuberculosis / microbiology

Substances

Antibiotics, Antitubercular
Rifabutin
Rifampin